<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04446845</url>
  </required_header>
  <id_info>
    <org_study_id>FSD-DUO-2020-02</org_study_id>
    <nct_id>NCT04446845</nct_id>
  </id_info>
  <brief_title>Double Stimulation Followed by a Fresh Embryo Transfer</brief_title>
  <acronym>DUO_STIM_FRESH</acronym>
  <official_title>Double vs. Single Stimulation in Young Poor Prognosis Patients Followed by a Fresh Embryo Transfer. A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Santiago Dexeus Font</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major goal of controlled ovarian stimulation (COS) is to increase the number of oocytes&#xD;
      harvested in order to result in the generation of a higher number of available embryos,&#xD;
      extended embryo culture, embryo selection and finally providing higher cumulative live birth&#xD;
      rates in infertile patients. Moreover, with the idea of the multiple waves of follicular&#xD;
      production, we could start to take full advantage of the whole follicular cohort, and not&#xD;
      only of the follicular wave.&#xD;
&#xD;
      In the context of low prognosis women such as women with poor ovarian response where, the&#xD;
      success rates are very low due to the low number of oocytes retrieved and consequently of&#xD;
      viable embryos), Dual stimulation may be of great value as a tool to improve outcomes.&#xD;
&#xD;
      The reported advantage of DuoStim is retrieved of more oocytes within a shorter time span,&#xD;
      resulting in an increase in the probability of having transferable embryos increases, and&#xD;
      theoretically reducing time to live birth as well as cycle cancellation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In assisted reproductive technologies (ART), despite the progress of the last decades, the&#xD;
      achievement of a live birth still remains a challenge, especially for some categories of&#xD;
      patients such as the one with poor ovarian reserve. One of the main tolls in reproductive&#xD;
      medicine is controlled ovarian stimulation (COS) which is performed with the aim of obtaining&#xD;
      multiple oocytes, so as to increase the chance of a live birth (LB) .&#xD;
&#xD;
      In order to induce multifollicular development in ovarian stimulation, recombinant FSH (or&#xD;
      other products based on FSH) are given at the beginning of the follicular phase for an&#xD;
      average of 10-12 days. The reason for this timing is mainly due to the fact that the&#xD;
      follicular phase is clearly the moment when the ovaries are recruiting new follicles in order&#xD;
      to establish the dominant for the cycle. However, as previously described follicular&#xD;
      production by the ovaries follows a pattern of multicyclic waves. More specifically, a wave&#xD;
      is a synchronous growth of follicles that have similar diameter and that can be documented&#xD;
      with ultrasound . Beside the very well-known follicular wave (which is the one exploited in&#xD;
      the COS), 64% of the women has two waves (follicular and luteal) and 32% of women has up to 3&#xD;
      waves in a normal cycle (early follicular, late follicular and luteal) .&#xD;
&#xD;
      The innovative concept of multiple waves of follicular development has been utilized in&#xD;
      previous studies aiming to evaluate the effect of more than 1 stimulation cycles in a short&#xD;
      period of time (less than 1 month). Specifically, two stimulation cycles have been performed&#xD;
      in the same cycle by previous researcher (starting from the classical follicular COS and&#xD;
      followed by a subsequent stimulation 5 days after the first oocyte retrieval) and it has been&#xD;
      shown to be associated with improved cycle outcomes, alias higher number of oocytes retrieved&#xD;
      and number of embryos obtained in total. Furthermore, in women with low ovarian response&#xD;
      recent studies have suggested that the luteal phase stimulation appears to result in a higher&#xD;
      number of oocytes retrieved as compared to the first follicular phase stimulation cycle .&#xD;
&#xD;
      Nevertheless, in spite of the accumulating evidence, a common characteristic of all of the&#xD;
      published trials up to date is that in all of them dual stimulation cycle was initiated in&#xD;
      the classical follicular phase followed by second stimulation cycle 5 days after oocytes&#xD;
      retrieval. This approach had two major limitations:&#xD;
&#xD;
        1. Owing to this extended protocol and the luteal phase start the lack of synchronization&#xD;
           between embryos and endometrium, a freeze-only protocol was considered essential to be&#xD;
           adopted .&#xD;
&#xD;
        2. The fact that the 2nd stimulation cycle (luteal phase) always started 5 days after the&#xD;
           first stimulation cycle does allow an unbiased evaluation of whether the improved&#xD;
           outcomes on the second cycle are attributed to the luteal phase initiation of&#xD;
           stimulation or to a carry-over effect of the first stimulation cycle.&#xD;
&#xD;
      Based on the above evidence we decided to design the current randomized trial which is, to&#xD;
      our knowledge, the first to evaluate the benefit from the dual stimulation approach, not&#xD;
      followed by a freeze-only strategy, but by fresh embryo transfer. In order to achieve this,&#xD;
      we aim to compare the COS with the double stimulation (first luteal stimulation and then&#xD;
      follicular ovarian stimulation) followed by fresh embryo transfer (ET) in poor prognosis&#xD;
      patients undergoing in vitro fertilization/intra-cytoplasmatic sperm injections (IVF/ICSI)&#xD;
      treatment.&#xD;
&#xD;
      The current randomized trial will allow us to&#xD;
&#xD;
        1. compare the double stimulation with a single stimulation strategy followed by fresh&#xD;
           embryo transfer and&#xD;
&#xD;
        2. perform comparison of a luteal phase (1st cycle of the double stimulation group) and a&#xD;
           follicular phase stimulation (control group) in a randomized setting&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Actual">May 2, 2023</completion_date>
  <primary_completion_date type="Actual">January 15, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of good-quality blastocysts</measure>
    <time_frame>Day of embryo transfer (9 -20 days from initiation of the last ovarian stimulation)</time_frame>
    <description>Embryo quality will be assessed according to the Istanbul consensus workshop criteria (Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Human Reproduction 2011) and good quality embryo (GQE) at this developmental will be an expanded through to hatched blastocyst with an inner cell mass (ICM) that is prominent, easily discernible and consisting of many cells, with the cells compacted and tightly adhered together, and with a trophectoderm (TE) that comprises many cells forming a cohesive epithelium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number oocytes retrieved</measure>
    <time_frame>9 -20 days from initiation of the last ovarian stimulation</time_frame>
    <description>The outcome will be evaluated on the day of oocyte retrieval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cycles reaching the stage of embryo transfer</measure>
    <time_frame>9 -20 days from initiation of the last ovarian stimulation</time_frame>
    <description>The outcome will be evaluated 5 days after last oocyte retrieval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>6-7 weeks of gestation</time_frame>
    <description>The presence of intrauterine gestational sac with an embryonic pole demonstrating cardiac activity at 6-7 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>8-10 weeks of gestation</time_frame>
    <description>The presence of intrauterine gestational sac with an embryonic pole demonstrating cardiac activity at 11-12 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pregnancy</measure>
    <time_frame>4-6 weeks of gestation</time_frame>
    <description>Days between beginning of first stimulation and clinical pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes between follicular phase or luteal phase initiation of ovarian stimulation</measure>
    <time_frame>9 -20 days from initiation of the ovarian stimulation</time_frame>
    <description>The outcome will be evaluated on the day of oocyte retrieval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Metaphase II oocytes (MII) between follicular phase or luteal phase initiation of ovarian stimulation</measure>
    <time_frame>9 -20 days from initiation of the ovarian stimulation</time_frame>
    <description>The outcome will be evaluated on the day of oocyte retrieval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total additional dose of recombinant follicle stimulating hormone (rFSH)</measure>
    <time_frame>9 -20 days from initiation of the ovarian stimulation</time_frame>
    <description>The outcome will be evaluated on the day of trigger</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stimulation</measure>
    <time_frame>9 -20 days from initiation of the ovarian stimulation</time_frame>
    <description>The outcome will be evaluated on the day of trigger</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine profile</measure>
    <time_frame>Day 1, Day 6 , Day 8 of stimulation and Day of trigger 9 -20 days from initiation of the ovarian stimulation in each ovarian stimulation cycle</time_frame>
    <description>Estradiol, Progesterone, luteinizing hormone (LH) and FSH</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 30 days from treatment start date</time_frame>
    <description>Any adverse event related with stimulation must be reported in Adverse Event Report Form</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Double Stimulation (Elonva+rFSH) in luteal /follicular phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp &amp; Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.&#xD;
A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.&#xD;
This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Stimulation (Elonva+rFSH) in follicular phase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double Stimulation (Elonva+rFSH) in luteal /follicular phase</intervention_name>
    <description>Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.</description>
    <arm_group_label>Double Stimulation (Elonva+rFSH) in luteal /follicular phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional Stimulation (Elonva+rFSH) in follicular phase</intervention_name>
    <description>From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.</description>
    <arm_group_label>Conventional Stimulation (Elonva+rFSH) in follicular phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Poor prognosis patients according to the POSEIDON group 3 &amp; 4 (based on AMH)&#xD;
&#xD;
          -  AMH &lt;1.2&#xD;
&#xD;
          -  age &lt;40 years old&#xD;
&#xD;
          -  BMI &gt;18 and &lt;35 kg/m2&#xD;
&#xD;
          -  Body weight &gt;50kg (in women &lt;36 years old body weight &gt;60kg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Maternal age &gt; 40 years&#xD;
&#xD;
          -  History of untreated autoimmune, endocrine or metabolic disorders&#xD;
&#xD;
          -  Previous ovarian cystectomy or oophorectomy&#xD;
&#xD;
          -  Body weight &lt;50kg (and body weight &lt;60kg in women &lt;36 years old)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaos P Polyzos, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hopital Universitari Dexeus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://dexeus.com</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Alsbjerg B, Haahr T, Elbaek HO, Laursen R, Povlsen BB, Humaidan P. Dual stimulation using corifollitropin alfa in 54 Bologna criteria poor ovarian responders - a case series. Reprod Biomed Online. 2019 May;38(5):677-682. doi: 10.1016/j.rbmo.2019.01.007. Epub 2019 Jan 22.</citation>
    <PMID>30795977</PMID>
  </reference>
  <reference>
    <citation>Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011 Jun;26(6):1270-83. doi: 10.1093/humrep/der037. Epub 2011 Apr 18.</citation>
    <PMID>21502182</PMID>
  </reference>
  <reference>
    <citation>Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003 Jul;80(1):116-22. doi: 10.1016/s0015-0282(03)00544-2.</citation>
    <PMID>12849812</PMID>
  </reference>
  <reference>
    <citation>Cardoso MCA, Evangelista A, Sartorio C, Vaz G, Werneck CLV, Guimaraes FM, Sa PG, Erthal MC. Can ovarian double-stimulation in the same menstrual cycle improve IVF outcomes? JBRA Assist Reprod. 2017 Sep 1;21(3):217-221. doi: 10.5935/1518-0557.20170042.</citation>
    <PMID>28837031</PMID>
  </reference>
  <reference>
    <citation>Coutifaris C. Freeze-only in vitro fertilization cycles for all? Fertil Steril. 2017 Aug;108(2):233-234. doi: 10.1016/j.fertnstert.2017.06.028. No abstract available.</citation>
    <PMID>28778278</PMID>
  </reference>
  <reference>
    <citation>Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, Polyzos NP. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016 Feb;31(2):370-6. doi: 10.1093/humrep/dev316. Epub 2016 Jan 2.</citation>
    <PMID>26724797</PMID>
  </reference>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <reference>
    <citation>Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, Shoham Z. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014 Jan;101(1):105-11. doi: 10.1016/j.fertnstert.2013.09.007. Epub 2013 Oct 23.</citation>
    <PMID>24161646</PMID>
  </reference>
  <reference>
    <citation>Liu C, Jiang H, Zhang W, Yin H. Double ovarian stimulation during the follicular and luteal phase in women &gt;/=38 years: a retrospective case-control study. Reprod Biomed Online. 2017 Dec;35(6):678-684. doi: 10.1016/j.rbmo.2017.08.019. Epub 2017 Aug 24.</citation>
    <PMID>29030068</PMID>
  </reference>
  <reference>
    <citation>Moffat R, Pirtea P, Gayet V, Wolf JP, Chapron C, de Ziegler D. Dual ovarian stimulation is a new viable option for enhancing the oocyte yield when the time for assisted reproductive technnology is limited. Reprod Biomed Online. 2014 Dec;29(6):659-61. doi: 10.1016/j.rbmo.2014.08.010. Epub 2014 Sep 4.</citation>
    <PMID>25311972</PMID>
  </reference>
  <reference>
    <citation>Morin SJ, Patounakis G, Juneau CR, Neal SA, Scott RT, Seli E. Diminished ovarian reserve and poor response to stimulation in patients &lt;38 years old: a quantitative but not qualitative reduction in performance. Hum Reprod. 2018 Aug 1;33(8):1489-1498. doi: 10.1093/humrep/dey238.</citation>
    <PMID>30010882</PMID>
  </reference>
  <reference>
    <citation>Polyzos NP, Nwoye M, Corona R, Blockeel C, Stoop D, Haentjens P, Camus M, Tournaye H. Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI. Reprod Biomed Online. 2014 Apr;28(4):469-74. doi: 10.1016/j.rbmo.2013.11.010. Epub 2013 Dec 4.</citation>
    <PMID>24581984</PMID>
  </reference>
  <reference>
    <citation>Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number); Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK, Ubaldi FM, Humaidan P. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016 Jun;105(6):1452-3. doi: 10.1016/j.fertnstert.2016.02.005. Epub 2016 Feb 26. No abstract available.</citation>
    <PMID>26921622</PMID>
  </reference>
  <reference>
    <citation>Sighinolfi G, Sunkara SK, La Marca A. New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation. Reprod Biomed Online. 2018 Oct;37(4):489-497. doi: 10.1016/j.rbmo.2018.07.006. Epub 2018 Aug 11.</citation>
    <PMID>30170909</PMID>
  </reference>
  <reference>
    <citation>Tsampras N, Gould D, Fitzgerald CT. Double ovarian stimulation (DuoStim) protocol for fertility preservation in female oncology patients. Hum Fertil (Camb). 2017 Dec;20(4):248-253. doi: 10.1080/14647273.2017.1287433. Epub 2017 Feb 9.</citation>
    <PMID>28423955</PMID>
  </reference>
  <reference>
    <citation>Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, Trabucco E, Venturella R, Vajta G, Rienzi L. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016 Jun;105(6):1488-1495.e1. doi: 10.1016/j.fertnstert.2016.03.002. Epub 2016 Mar 25.</citation>
    <PMID>27020168</PMID>
  </reference>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>May 12, 2023</last_update_submitted>
  <last_update_submitted_qc>May 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04446845
org study id: FSD-DUO-2020-02
nct id: NCT04446845
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The major goal of controlled ovarian stimulation (COS) is to increase the number of oocytes
      harvested in order to result in the generation of a higher number of available embryos,
      extended embryo culture, embryo selection and finally providing higher cumulative live birth
      rates in infertile patients. Moreover, with the idea of the multiple waves of follicular
      production, we could start to take full advantage of the whole follicular cohort, and not
      only of the follicular wave.

      In the context of low prognosis women such as women with poor ovarian response where, the
      success rates are very low due to the low number of oocytes retrieved and consequently of
      viable embryos), Dual stimulation may be of great value as a tool to improve outcomes.

      The reported advantage of DuoStim is retrieved of more oocytes within a shorter time span,
      resulting in an increase in the probability of having transferable embryos increases, and
      theoretically reducing time to live birth as well as cycle cancellation.
In assisted reproductive technologies (ART), despite the progress of the last decades, the
      achievement of a live birth still remains a challenge, especially for some categories of
      patients such as the one with poor ovarian reserve. One of the main tolls in reproductive
      medicine is controlled ovarian stimulation (COS) which is performed with the aim of obtaining
      multiple oocytes, so as to increase the chance of a live birth (LB) .

      In order to induce multifollicular development in ovarian stimulation, recombinant FSH (or
      other products based on FSH) are given at the beginning of the follicular phase for an
      average of 10-12 days. The reason for this timing is mainly due to the fact that the
      follicular phase is clearly the moment when the ovaries are recruiting new follicles in order
      to establish the dominant for the cycle. However, as previously described follicular
      production by the ovaries follows a pattern of multicyclic waves. More specifically, a wave
      is a synchronous growth of follicles that have similar diameter and that can be documented
      with ultrasound . Beside the very well-known follicular wave (which is the one exploited in
      the COS), 64% of the women has two waves (follicular and luteal) and 32% of women has up to 3
      waves in a normal cycle (early follicular, late follicular and luteal) .

      The innovative concept of multiple waves of follicular development has been utilized in
      previous studies aiming to evaluate the effect of more than 1 stimulation cycles in a short
      period of time (less than 1 month). Specifically, two stimulation cycles have been performed
      in the same cycle by previous researcher (starting from the classical follicular COS and
      followed by a subsequent stimulation 5 days after the first oocyte retrieval) and it has been
      shown to be associated with improved cycle outcomes, alias higher number of oocytes retrieved
      and number of embryos obtained in total. Furthermore, in women with low ovarian response
      recent studies have suggested that the luteal phase stimulation appears to result in a higher
      number of oocytes retrieved as compared to the first follicular phase stimulation cycle .

      Nevertheless, in spite of the accumulating evidence, a common characteristic of all of the
      published trials up to date is that in all of them dual stimulation cycle was initiated in
      the classical follicular phase followed by second stimulation cycle 5 days after oocytes
      retrieval. This approach had two major limitations:

        1. Owing to this extended protocol and the luteal phase start the lack of synchronization
           between embryos and endometrium, a freeze-only protocol was considered essential to be
           adopted .

        2. The fact that the 2nd stimulation cycle (luteal phase) always started 5 days after the
           first stimulation cycle does allow an unbiased evaluation of whether the improved
           outcomes on the second cycle are attributed to the luteal phase initiation of
           stimulation or to a carry-over effect of the first stimulation cycle.

      Based on the above evidence we decided to design the current randomized trial which is, to
      our knowledge, the first to evaluate the benefit from the dual stimulation approach, not
      followed by a freeze-only strategy, but by fresh embryo transfer. In order to achieve this,
      we aim to compare the COS with the double stimulation (first luteal stimulation and then
      follicular ovarian stimulation) followed by fresh embryo transfer (ET) in poor prognosis
      patients undergoing in vitro fertilization/intra-cytoplasmatic sperm injections (IVF/ICSI)
      treatment.

      The current randomized trial will allow us to

        1. compare the double stimulation with a single stimulation strategy followed by fresh
           embryo transfer and

        2. perform comparison of a luteal phase (1st cycle of the double stimulation group) and a
           follicular phase stimulation (control group) in a randomized setting
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Number of good-quality blastocysts
time frame: Day of embryo transfer (9 -20 days from initiation of the last ovarian stimulation)
description: Embryo quality will be assessed according to the Istanbul consensus workshop criteria (Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Human Reproduction 2011) and good quality embryo (GQE) at this developmental will be an expanded through to hatched blastocyst with an inner cell mass (ICM) that is prominent, easily discernible and consisting of many cells, with the cells compacted and tightly adhered together, and with a trophectoderm (TE) that comprises many cells forming a cohesive epithelium
measure: Number oocytes retrieved
time frame: 9 -20 days from initiation of the last ovarian stimulation
description: The outcome will be evaluated on the day of oocyte retrieval
measure: Number of cycles reaching the stage of embryo transfer
time frame: 9 -20 days from initiation of the last ovarian stimulation
description: The outcome will be evaluated 5 days after last oocyte retrieval
measure: Clinical pregnancy
time frame: 6-7 weeks of gestation
description: The presence of intrauterine gestational sac with an embryonic pole demonstrating cardiac activity at 6-7 weeks of gestation
measure: Ongoing pregnancy
time frame: 8-10 weeks of gestation
description: The presence of intrauterine gestational sac with an embryonic pole demonstrating cardiac activity at 11-12 weeks of gestation
measure: Time to pregnancy
time frame: 4-6 weeks of gestation
description: Days between beginning of first stimulation and clinical pregnancy
measure: Number of oocytes between follicular phase or luteal phase initiation of ovarian stimulation
time frame: 9 -20 days from initiation of the ovarian stimulation
description: The outcome will be evaluated on the day of oocyte retrieval
measure: Number of Metaphase II oocytes (MII) between follicular phase or luteal phase initiation of ovarian stimulation
time frame: 9 -20 days from initiation of the ovarian stimulation
description: The outcome will be evaluated on the day of oocyte retrieval
measure: Total additional dose of recombinant follicle stimulating hormone (rFSH)
time frame: 9 -20 days from initiation of the ovarian stimulation
description: The outcome will be evaluated on the day of trigger
measure: Length of stimulation
time frame: 9 -20 days from initiation of the ovarian stimulation
description: The outcome will be evaluated on the day of trigger
measure: Endocrine profile
time frame: Day 1, Day 6 , Day 8 of stimulation and Day of trigger 9 -20 days from initiation of the ovarian stimulation in each ovarian stimulation cycle
description: Estradiol, Progesterone, luteinizing hormone (LH) and FSH
measure: Adverse events
time frame: Up to 30 days from treatment start date
description: Any adverse event related with stimulation must be reported in Adverse Event Report Form
arm group label: Double Stimulation (Elonva+rFSH) in luteal /follicular phase
arm group type: Experimental
description: A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp & Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.
A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.
This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)
arm group label: Conventional Stimulation (Elonva+rFSH) in follicular phase
arm group type: Active Comparator
description: A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG
intervention type: Drug
intervention name: Double Stimulation (Elonva+rFSH) in luteal /follicular phase
description: Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
arm group label: Double Stimulation (Elonva+rFSH) in luteal /follicular phase
intervention type: Drug
intervention name: Conventional Stimulation (Elonva+rFSH) in follicular phase
description: From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
arm group label: Conventional Stimulation (Elonva+rFSH) in follicular phase
criteria: 
gender: Female
minimum age: 18 Years
maximum age: 40 Years
healthy volunteers: No
last name: Nikolaos P Polyzos, MD PhD
role: Study Director
affiliation: Hopital Universitari Dexeus
facility: 
country: Spain
url: http://dexeus.com
description: Related Info
citation: Alsbjerg B, Haahr T, Elbaek HO, Laursen R, Povlsen BB, Humaidan P. Dual stimulation using corifollitropin alfa in 54 Bologna criteria poor ovarian responders - a case series. Reprod Biomed Online. 2019 May;38(5):677-682. doi: 10.1016/j.rbmo.2019.01.007. Epub 2019 Jan 22.
PMID: 30795977
citation: Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011 Jun;26(6):1270-83. doi: 10.1093/humrep/der037. Epub 2011 Apr 18.
PMID: 21502182
citation: Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril. 2003 Jul;80(1):116-22. doi: 10.1016/s0015-0282(03)00544-2.
PMID: 12849812
citation: Cardoso MCA, Evangelista A, Sartorio C, Vaz G, Werneck CLV, Guimaraes FM, Sa PG, Erthal MC. Can ovarian double-stimulation in the same menstrual cycle improve IVF outcomes? JBRA Assist Reprod. 2017 Sep 1;21(3):217-221. doi: 10.5935/1518-0557.20170042.
PMID: 28837031
citation: Coutifaris C. Freeze-only in vitro fertilization cycles for all? Fertil Steril. 2017 Aug;108(2):233-234. doi: 10.1016/j.fertnstert.2017.06.028. No abstract available.
PMID: 28778278
citation: Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, Polyzos NP. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016 Feb;31(2):370-6. doi: 10.1093/humrep/dev316. Epub 2016 Jan 2.
PMID: 26724797
citation: Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.
PMID: 21505041
citation: Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, Shoham Z. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril. 2014 Jan;101(1):105-11. doi: 10.1016/j.fertnstert.2013.09.007. Epub 2013 Oct 23.
PMID: 24161646
citation: Liu C, Jiang H, Zhang W, Yin H. Double ovarian stimulation during the follicular and luteal phase in women >/=38 years: a retrospective case-control study. Reprod Biomed Online. 2017 Dec;35(6):678-684. doi: 10.1016/j.rbmo.2017.08.019. Epub 2017 Aug 24.
PMID: 29030068
citation: Moffat R, Pirtea P, Gayet V, Wolf JP, Chapron C, de Ziegler D. Dual ovarian stimulation is a new viable option for enhancing the oocyte yield when the time for assisted reproductive technnology is limited. Reprod Biomed Online. 2014 Dec;29(6):659-61. doi: 10.1016/j.rbmo.2014.08.010. Epub 2014 Sep 4.
PMID: 25311972
citation: Morin SJ, Patounakis G, Juneau CR, Neal SA, Scott RT, Seli E. Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance. Hum Reprod. 2018 Aug 1;33(8):1489-1498. doi: 10.1093/humrep/dey238.
PMID: 30010882
citation: Polyzos NP, Nwoye M, Corona R, Blockeel C, Stoop D, Haentjens P, Camus M, Tournaye H. Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI. Reprod Biomed Online. 2014 Apr;28(4):469-74. doi: 10.1016/j.rbmo.2013.11.010. Epub 2013 Dec 4.
PMID: 24581984
citation: Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number); Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, Fischer R, Galliano D, Polyzos NP, Sunkara SK, Ubaldi FM, Humaidan P. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016 Jun;105(6):1452-3. doi: 10.1016/j.fertnstert.2016.02.005. Epub 2016 Feb 26. No abstract available.
PMID: 26921622
citation: Sighinolfi G, Sunkara SK, La Marca A. New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation. Reprod Biomed Online. 2018 Oct;37(4):489-497. doi: 10.1016/j.rbmo.2018.07.006. Epub 2018 Aug 11.
PMID: 30170909
citation: Tsampras N, Gould D, Fitzgerald CT. Double ovarian stimulation (DuoStim) protocol for fertility preservation in female oncology patients. Hum Fertil (Camb). 2017 Dec;20(4):248-253. doi: 10.1080/14647273.2017.1287433. Epub 2017 Feb 9.
PMID: 28423955
citation: Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, Trabucco E, Venturella R, Vajta G, Rienzi L. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016 Jun;105(6):1488-1495.e1. doi: 10.1016/j.fertnstert.2016.03.002. Epub 2016 Mar 25.
PMID: 27020168
responsible party type: Sponsor
mesh term: Infertility
sharing ipd: No